NO20052579L - Derviater av (6,7-dihydro-5h-imidazo(i,2-a) imidazol-3-sulfonylamino)-pro pionamid - Google Patents

Derviater av (6,7-dihydro-5h-imidazo(i,2-a) imidazol-3-sulfonylamino)-pro pionamid

Info

Publication number
NO20052579L
NO20052579L NO20052579A NO20052579A NO20052579L NO 20052579 L NO20052579 L NO 20052579L NO 20052579 A NO20052579 A NO 20052579A NO 20052579 A NO20052579 A NO 20052579A NO 20052579 L NO20052579 L NO 20052579L
Authority
NO
Norway
Prior art keywords
propionamide
imidazo
dihydro
imidazole
derviates
Prior art date
Application number
NO20052579A
Other languages
English (en)
Norwegian (no)
Inventor
Terence Alfred Kelly
Jin Mi Kim
Rene Marc Lemieux
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20052579L publication Critical patent/NO20052579L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20052579A 2002-10-30 2005-05-27 Derviater av (6,7-dihydro-5h-imidazo(i,2-a) imidazol-3-sulfonylamino)-pro pionamid NO20052579L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42244602P 2002-10-30 2002-10-30
PCT/US2003/033865 WO2004041827A2 (en) 2002-10-30 2003-10-27 DERIVATIVES OF [6,7-DIHYDRO-5H-IMIDAZO[1,2-α] IMIDAZOLE-3-SULFONYLAMINO]-PROPIONAMIDE AND THEIR USE AS INHIBITORS UPON THE INTERACTION OF CAMS AND LEUKO INTEGRINS

Publications (1)

Publication Number Publication Date
NO20052579L true NO20052579L (no) 2005-05-27

Family

ID=32312506

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052579A NO20052579L (no) 2002-10-30 2005-05-27 Derviater av (6,7-dihydro-5h-imidazo(i,2-a) imidazol-3-sulfonylamino)-pro pionamid

Country Status (32)

Country Link
US (4) US6844360B2 (el)
EP (1) EP1560830B1 (el)
JP (1) JP4366477B2 (el)
KR (1) KR20050067426A (el)
CN (1) CN1708500A (el)
AR (1) AR041854A1 (el)
AT (1) ATE343582T1 (el)
AU (1) AU2003284938A1 (el)
BR (1) BR0315836A (el)
CA (1) CA2504219A1 (el)
CO (1) CO5690604A2 (el)
CY (1) CY1106258T1 (el)
DE (1) DE60309344T2 (el)
DK (1) DK1560830T3 (el)
EA (1) EA008443B1 (el)
EC (1) ECSP055823A (el)
ES (1) ES2276134T3 (el)
HR (1) HRP20050387A2 (el)
MX (1) MXPA05004480A (el)
MY (1) MY136822A (el)
NO (1) NO20052579L (el)
NZ (1) NZ540269A (el)
PE (1) PE20040782A1 (el)
PL (1) PL375709A1 (el)
PT (1) PT1560830E (el)
RS (1) RS20050327A (el)
SI (1) SI1560830T1 (el)
TW (1) TW200424204A (el)
UA (1) UA80160C2 (el)
UY (1) UY28049A1 (el)
WO (1) WO2004041827A2 (el)
ZA (1) ZA200502701B (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492408B1 (en) * 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
EP1712553A3 (en) * 2002-10-30 2006-11-02 Boehringer Ingelheim Pharmaceuticals, Inc. Derivates of [6, 7-dihydro - 5H - imidazo[1,2- alpha]imidazole-3-sulfonylamino]-propionamide and their use as inhibitors upon the interaction of CAMS and leukointegrins
US6844360B2 (en) * 2002-10-30 2005-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide
US6852748B1 (en) * 2002-10-30 2005-02-08 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide
US8699508B2 (en) * 2003-12-18 2014-04-15 Intel Corporation Response scheduling for multiple receivers
JP2008506786A (ja) * 2004-07-27 2008-03-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ６，７−ジヒドロ−５Ｈ−イミダゾ［１，２−ａ］イミダゾール−３−スルホン酸アミドの合成
JP2008536834A (ja) * 2005-04-06 2008-09-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ［６，７−ジヒドロ−５Ｈイミダゾ［１，２−α］イミダゾール−３−スルホニル］−アゼテジン−カルボン酸、エステル及びアミドの誘導体及び抗炎症薬としてのそれらの使用
CA2607999A1 (en) * 2005-05-19 2007-03-08 Boehringer Ingelheim International Gmbh Derivatives of 6,7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonic acid
US20070173517A1 (en) * 2006-01-20 2007-07-26 Thomas Wirth Synthesis of 6,7-Dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides
US8552205B2 (en) * 2007-11-29 2013-10-08 Boehringer Ingelheim International Gmbh Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides
EP2445914B1 (en) 2009-06-02 2015-07-22 Boehringer Ingelheim International GmbH DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
DK2445909T3 (da) * 2009-06-02 2014-02-10 Boehringer Ingelheim Int Derivater af 6,7-dihydro-5h-imidazo [1,2-a] imidazol-3-carboxylsyre amider
WO2021217040A1 (en) * 2020-04-24 2021-10-28 Immvention Therapeutix Carbamate and urea derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0966447T3 (da) 1997-03-03 2003-06-23 Boehringer Ingelheim Pharma Anvendelige små molekyler til behandling af betændelsessygdomme
US6355664B1 (en) 1997-03-03 2002-03-12 Boehringer Ingelheim Pharmaceuticals, Inc. Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease
US6492408B1 (en) * 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
EP1309595A2 (en) * 2000-08-09 2003-05-14 Boehringer Ingelheim Pharmaceuticals Inc. Synthesis of (r)-3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1-h-imidazo(1,2-a) imidazol-2-one
US6844360B2 (en) * 2002-10-30 2005-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide
US6852748B1 (en) * 2002-10-30 2005-02-08 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide

Also Published As

Publication number Publication date
MY136822A (en) 2008-11-28
HRP20050387A2 (en) 2006-10-31
PE20040782A1 (es) 2004-12-16
PL375709A1 (en) 2005-12-12
US20080090819A1 (en) 2008-04-17
DE60309344T2 (de) 2007-02-08
MXPA05004480A (es) 2005-07-26
US7304067B2 (en) 2007-12-04
ZA200502701B (en) 2005-10-13
US6844360B2 (en) 2005-01-18
ATE343582T1 (de) 2006-11-15
EA008443B1 (ru) 2007-06-29
US20050165027A1 (en) 2005-07-28
SI1560830T1 (sl) 2007-02-28
CA2504219A1 (en) 2004-05-21
WO2004041827A3 (en) 2004-07-15
EP1560830A2 (en) 2005-08-10
DE60309344D1 (de) 2006-12-07
ECSP055823A (es) 2005-08-11
RS20050327A (en) 2007-06-04
KR20050067426A (ko) 2005-07-01
BR0315836A (pt) 2005-09-13
UY28049A1 (es) 2004-05-31
ES2276134T3 (es) 2007-06-16
US7589115B2 (en) 2009-09-15
TW200424204A (en) 2004-11-16
DK1560830T3 (da) 2007-02-26
CY1106258T1 (el) 2011-06-08
EP1560830B1 (en) 2006-10-25
EA200500603A1 (ru) 2005-10-27
PT1560830E (pt) 2007-01-31
JP4366477B2 (ja) 2009-11-18
US7345074B2 (en) 2008-03-18
AU2003284938A1 (en) 2004-06-07
AR041854A1 (es) 2005-06-01
UA80160C2 (en) 2007-08-27
US20040127534A1 (en) 2004-07-01
JP2006508947A (ja) 2006-03-16
CN1708500A (zh) 2005-12-14
CO5690604A2 (es) 2006-10-31
WO2004041827A2 (en) 2004-05-21
US20050054703A1 (en) 2005-03-10
NZ540269A (en) 2007-05-31

Similar Documents

Publication Publication Date Title
NO20052579L (no) Derviater av (6,7-dihydro-5h-imidazo(i,2-a) imidazol-3-sulfonylamino)-pro pionamid
DK1761542T3 (da) Octahydropyrrolo[3,4-C] pyrrolderivater og anvendelsen deraf som antivirusmidler
AU2002341920A1 (en) Chemical compounds
NO20053955D0 (no) Pyrazolo [1,5-A] pyrimidinderivater
NO20053600D0 (no) Pyrazolo (3,4-b)pyridinforbindelser og anvendelse derav som fosfodiesterase inhibitorer.
DE60206946D1 (de) Substituierte 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)onderivate gegen neurodegenerative erkrankungen
NO20070782L (no) Tetrapeptidanaloger.
DK1754707T3 (da) Multicykliske forbindelser og anvendelse deraf som inhibitorer af PARP-, VEGFR2- og MLK3-enzymer
NO20033651L (no) Cancerbehandling
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA201000866A1 (ru) Производные амидов 6,7-дигидро-5н-имидазо[1,2-а]имидазол-3-карбоновой кислоты
DK1608654T3 (da) 8-substituerede-6, 7, 8, 9-tetrahydropyrimido (1,2- a) pyrimidin-4-on-derivater
ATE269333T1 (de) 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2- a)pyrimidin-4-on- und 7-pyridinyl-2,3- dihydroimidazo(1,2-a)pyrimidin-5 1honderivate
EA200800223A1 (ru) ПРОИЗВОДНЫЕ ПИРИДО[2,3-d]ПИРИМИДИНА, ИХ ПОЛУЧЕНИЕ, ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
NO20031648L (no) Farmasöytiske lösninger av modafinilforbindelser
NO20053903L (no) Nukleotidlipidesterderivater.
TW200722426A (en) Derivatives of 6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-sulfonic acid
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
EG24959A (en) Indoles useful in the treatment of androgenreceptor related diseases.
EA200601128A1 (ru) Пиразолопиримидины
EP1436279A4 (en) CHEMICAL COMPOUNDS
DE60106947D1 (de) Oxindolderivate
WO2004056762A3 (en) Novel aminobenzophenone compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application